Abstract
The in vitro evaluation of a series of (hetero)aromatic-substituted 4-hydroxycyclohexa-2,5-dienones (quinols) and analogues against M. tuberculosis is reported. The most active compound in the series was found to be 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone 1a with a minimum inhibitory concentration of 0.78 μg/mL. Biochemical evidence for involvement of the small redox protein thioredoxin C - a novel drug target - is also presented.
Keywords: Antitubercular activity, Mycobacterium tuberculosis (MTb), quinols, thioredoxin
Letters in Drug Design & Discovery
Title: Antitubercular Properties of Substituted Hydroxycyclohexadienones
Volume: 3 Issue: 6
Author(s): Manish Shah, Geoffrey Wells, Tracey D. Bradshaw, Charles A. Laughton, Malcolm F.G. Stevens and Andrew D. Westwell
Affiliation:
Keywords: Antitubercular activity, Mycobacterium tuberculosis (MTb), quinols, thioredoxin
Abstract: The in vitro evaluation of a series of (hetero)aromatic-substituted 4-hydroxycyclohexa-2,5-dienones (quinols) and analogues against M. tuberculosis is reported. The most active compound in the series was found to be 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone 1a with a minimum inhibitory concentration of 0.78 μg/mL. Biochemical evidence for involvement of the small redox protein thioredoxin C - a novel drug target - is also presented.
Export Options
About this article
Cite this article as:
Shah Manish, Wells Geoffrey, Bradshaw D. Tracey, Laughton A. Charles, Stevens F.G. Malcolm and Westwell D. Andrew, Antitubercular Properties of Substituted Hydroxycyclohexadienones, Letters in Drug Design & Discovery 2006; 3 (6) . https://dx.doi.org/10.2174/157018006777805486
DOI https://dx.doi.org/10.2174/157018006777805486 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigating Human P450s Involved in Drug Metabolism via Homology with High-Resolution P450 Crystal Structures of the CYP2C Subfamily
Current Drug Metabolism Quality by Design Approach for Development and Optimization of Rifampicin Loaded Bovine Serum Albumin Nanoparticles and Characterization
Current Drug Delivery Protective Mechanisms of Helminths Against Reactive Oxygen Species are Highly Promising Drug Targets
Current Medicinal Chemistry An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Meet Our Editorial Board Member
Current Medicinal Chemistry Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Exploring Novel Immunological Interventions Using Immunoinfectomics
Anti-Infective Agents Nrf2/HO-1 Mediated Antioxidant Activities, Cytotoxicity Analysis and LCESI/ MS Profiling of Eulophia nuda L.
The Natural Products Journal Controlling Biofilms of Gram-Positive Pathogenic Bacteria
Current Medicinal Chemistry Mathematical Descriptors for the Prediction of Property, Bioactivity, and Toxicity of Chemicals from their Structure: A Chemical-Cum-Biochemical Approach
Current Computer-Aided Drug Design Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry <i>Dichrostachys cinerea</i>: Ethnomedicinal Uses, Phytochemistry and Pharmacological Activities - A Review
The Natural Products Journal Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Advances in Nanoparticles as Anticancer Drug Delivery Vector: Need of this Century
Current Pharmaceutical Design Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery Enoyl Reductases as Targets for the Development of Anti-Tubercular and Anti-Malarial Agents
Current Drug Targets COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety